AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Grandfield & Dodd LLC

Grandfield & Dodd LLC decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 16.4% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 7,426 shares of the company’s stock after selling 1,455 shares during the quarter. Grandfield & Dodd LLC’s holdings in AstraZeneca were worth $579,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Martin Investment Management LLC lifted its position in AstraZeneca by 2.8% in the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares during the period. Integrated Advisors Network LLC increased its position in AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after purchasing an additional 13,860 shares during the last quarter. Creative Planning boosted its holdings in AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after acquiring an additional 16,692 shares during the last quarter. Northcape Wealth Management LLC purchased a new position in AstraZeneca in the second quarter valued at approximately $269,000. Finally, Cetera Advisors LLC lifted its stake in shares of AstraZeneca by 124.5% during the first quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock worth $6,657,000 after purchasing an additional 54,488 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on AZN shares. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. TD Cowen upped their target price on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

Shares of AZN opened at $63.80 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company has a market capitalization of $197.82 billion, a price-to-earnings ratio of 30.53, a P/E/G ratio of 1.17 and a beta of 0.47. The business’s 50-day moving average is $74.34 and its 200-day moving average is $78.06. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.87 earnings per share. Equities research analysts expect that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.